Investigational Drug May Boost Survival in Men with Metastatic PCa


An investigational new agent called tasquinimod may help increase survival in men with metastatic prostate cancer

This oral agent has been found to extend progression-free survival by a mean of 7.6 months compared with 3.3 months for placebo.

John Schieszer has the latest on this new agent in today's Medical Minute.

Loading links....
You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters